Asston Pharmaceuticals Limited Press Release Oct 01 2026
Filed with BSE · · 3 pages · English
Summary by 6ix AI
Asston Pharmaceuticals Limited has filed a notice regarding the approval of several resolutions by its members at the recent Annual General Meeting. These resolutions include the adoption of audited financial statements for the previous financial year and the re-appointment of the Managing Director. Additionally, the company has appointed new statutory auditors and approved increases in remuneration for certain directors. This filing is made in compliance with the SEBI regulations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
1. Receipt, consideration and adoption of the Audited Standalone financial statements of the Company for the financial year ended March 31, 2026 together with the reports of Board of Directors and of the Auditors thereon. 3. Approved appointment of M/s Panchal S K & Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989W) as Statutory Auditors of the Company (Annexure-B).
Asston Pharmaceuticals Limited on 6ix
Earlier from Asston Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Asston Pharmaceuticals Limited Press Release Sep 29 2026
- Asston Pharmaceuticals Limited Press Release Sep 27 2026
- Asston Pharmaceuticals Limited Press Release Sep 07 2026
Later from Asston Pharmaceuticals
- Board Meeting Intimation for To Consider And Approve The Following Matters As Attached
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Follow Asston Pharmaceuticals into a list and get an email when it puts out news.
Follow Asston Pharmaceuticals